代谢分型定义胶质母细胞瘤亚型及其预后与治疗脆弱性
该研究对三个公开数据集的IDH野生型胶质母细胞瘤进行多组学分析,基于预后代谢相关基因定义三种转录亚型并在独立数据集和患者来源细胞模型中验证。M1富集突触信号和氨基酸代谢,M2以线粒体代谢和细胞周期为特征且生存较好,M3以缺氧、免疫激活与抑制及广泛代谢通路参与为标志且预后差。M3细胞对靶向糖胺聚糖降解、烟酰胺代谢和维甲酸通路的抑制剂在体内外模型中均显示高敏感性。
要点
- IDH野生型GBM可分M1、M2、M3三种代谢亚型,预后与代谢特征各异。
- M3亚型预后差,对糖胺聚糖降解、烟酰胺代谢和维甲酸通路抑制剂敏感。
- 亚型在独立队列和患者来源细胞模型中可重复验证。
核心结论
- IDH野生型GBM可定义为三种生物学和临床相关的代谢亚型,揭示不同代谢程序和治疗脆弱性,为精准代谢靶向策略提供框架。
研究设计与样本
- 对三个公开数据集的IDH野生型GBM进行多组学分析,用预后代谢相关基因定义转录亚型,在独立数据集和患者来源细胞模型中验证,并行功能实验和药物敏感性研究。
主要发现
- M1亚型富集突触信号和氨基酸代谢,具有前沿解剖特征。
- M2亚型以线粒体代谢和细胞周期活动为特征,与较好生存相关。
- M3亚型以缺氧、免疫激活与抑制及广泛代谢通路参与为标志,与不良预后相关。
- 亚型在多个队列中可重复,并在患者来源细胞模型中忠实再现。
- 代谢组学分析证实各亚型具有独特的代谢特征。
关键数值与推荐
- M3细胞在体外和体内模型中对靶向糖胺聚糖降解、烟酰胺代谢和维甲酸通路的抑制剂均显示高敏感性。
临床怎么用
- 基于代谢基因表达对IDH野生型GBM进行亚型分类,可识别M3等高治疗脆弱性亚群,指导精准代谢靶向治疗探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is a highly aggressive brain tumor with profound metabolic heterogeneity. However, a clinically actionable classification based on metabolic gene expression remains undefined. METHODS: We conducted a comprehensive multi-omics analysis of IDH-wildtype GBMs from three publicly available datasets. Prognostic metabolism-related genes were used to define transcriptional subtypes, which were validated in independent datasets and patient-derived cell (PDC) models. Functional assays and drug sensitivity studies were performed to explore therapeutic relevance. RESULTS: We identified three distinct metabolic subtypes: M1, enriched for synaptic signaling and amino acid metabolism, exhibited leading-edge anatomical features; M2, characterized by mitochondrial metabolism and cell cycle activity, was associated with favorable survival; and M3, marked by hypoxia, immune activation and suppression, and broad metabolic pathway engagement, correlated with poor prognosis. These subtypes were reproducible across cohorts and faithfully recapitulated in PDC models. Metabolomic profiling confirmed distinct subtype-specific metabolic signatures. Notably, M3 cells showed high sensitivity to inhibitors targeting glycosaminoglycan degradation, nicotinamide metabolism, and retinoic acid pathways in both in vitro and in vivo models. CONCLUSION: Our study defines three biologically and clinically relevant metabolic subtypes of IDH-wildtype GBM. This classification reveals distinct metabolic programs and therapeutic vulnerabilities, providing a framework for precision metabolism-targeted strategies in GBM.
引用
- Wu F, Yin YY, Wang D, et al. Metabolic profiling defines glioblastoma subtypes with distinct prognoses and therapeutic vulnerabilities. Neuro Oncol. 2026. PMID: 41485080. doi:10.1093/neuonc/noaf294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。